Contact Us
Drug Search Results
More Filters [+]

Abacavir

Alternative Names: abacavir, ziagen, epzicom, prurisol, km-133, abacavir sulfate, triumeq, trizivir, triumeq pd
Latest Update: 2024-12-05
Latest Update Note: Clinical Trial Update

Product Description

Abacavir is used along with other medications to treat human immunodeficiency virus (HIV) infection. Abacavir is in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). It works by decreasing the amount of HIV in the blood. Although abacavir does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other lifestyle changes may decrease the risk of transmitting (spreading) the HIV virus to other people. (Sourced from: https://medlineplus.gov/druginfo/meds/a699012.html)

Mechanisms of Action: NRT Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: HIV Infections | HIV Infections | HIV Infections | HIV Infections

Known Adverse Events: Headache Disorders | Headache | Chills | Migraine Disorders | Depressive Disorder | Dizziness | Insomnia | Vertigo | Drug Hypersensitivity | Diarrhea | HIV Infections

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Abacavir

Countries in Clinic:

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: HIV Infections

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
DOBINeuro

P3

Active, not recruiting

HIV Infections

2023-02-24

Recent News Events

Date

Type

Title

07/31/2024

News Article

 ViiV Healthcare announces positive data demonstrating 2-drug regimen DOVATO is as effective as 3-drug regimen BIKTARVY for maintenance therapy of HIV-1

07/23/2024

News Article

 ViiV Healthcare announces positive data demonstrating 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy for maintenance therapy of HIV-1

05/14/2024

News Article

 HIV Drugs Market Size Expected to Reach USD 49.68 Bn by 2032

05/09/2024

News Article

 Pharmacogenomics Market Worth $19.5 billion by 2031 -- Exclusive Report by Meticulous Research®

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions